SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 45 400 KRW 1% Market Closed
Market Cap: 3.6T KRW

EV/EBIT
Enterprise Value to EBIT

-25.2
Current
12.4
Median
4.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-25.2
=
Enterprise Value
2.8T KRW
/
EBIT
-110B KRW
EBIT Growth EV/EBIT to Growth
KR
SK Bioscience Co Ltd
KRX:302440
Average EV/EBIT: 19.8
Negative Multiple: -25.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 185.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -338.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-25.4
2-Years Forward
EV/EBIT
-46
3-Years Forward
EV/EBIT
-52.7